Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
But with the obvious buyer, Bristol, having apparently been outbid, there might be questions over Acceleron’s takeout price.
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.